The change of disease burden of CRD by categories in Fujian, 1990-2021. by Yanrong Yin (14292683)

Subjects:

The change of disease burden of CRD in different region, 1990-2021. by Yanrong Yin (14292683)

Subjects:

Sociodemographic characteristics of participants at baseline, overall and by age group. by Chelsea S. Lutz (16001569)

Subjects:

Symptoms self-reported and/or documented in the electronic health record during the acute COVID-19 illness, by hospitalization status and age group. by Chelsea S. Lutz (16001569)

Subjects:

Sociodemographic and clinical characteristics associated with PCC at three months post-acute illness among adults enrolled during Omicron predominance. by Chelsea S. Lutz (16001569)

Subjects:

Manifestations of Post-COVID-19 Conditions (PCC) three months post-acute illness, among those with PCC, by age group^a. by Chelsea S. Lutz (16001569)

Subjects:

Clinical outcomes and COVID-19 treatment during acute illness, by hospitalization status and age group. by Chelsea S. Lutz (16001569)

Subjects:

Initial participants by wave*. by Yeo Ju Sohn (18536198)

Subjects:

General characteristics of research participants. by Yeo Ju Sohn (18536198)

Subjects:

Risk of fracture with competing risk in denosumab users versus non-users. by Arisa Kobayashi (4379608)

Subjects:

BST2 overexpression decreased RSV multiplication. by Katherine Marougka (13015146)

Persistence and Recovery of ZIF‑8 and ZIF-67 Phytotoxicity by Xiaolin Zhang (246784)

“…Understanding the environmental risks of ZIFs is a prerequisite to their safe application by industry and new chemical registration by governments; however, the persistence and recovery of toxicity induced by ZIFs remain largely unclear. …”

The rationale of molecular design of new DNA-intercalators. by Ahmed A. Gaber (13302308)

QUIPS risk of bias assessment. by Nabeela Arbee-Kalidas (17598969)

“…Higher estimates of peak, measured and as a percentagege of predicted, showed significant associations with a lower risk of mortality [MD: 3.66, 95% CI: 0.88; 6.43 and MD: 16.49, 95% CI: 6.92; 26.07] and fewer complications [MD: 2.06, 95% CI: 1.12; 3.00 and MD: 9.82, 95% CI: 5.88; 13.76]. …”

Publication bias of the risk of all groups. by Juan Gu (288925)

“…A period of 10–20 years since the last birth also showed a decreased risk (OR=0.867; 95% CI:0.747–1.007), whereas more than 20 years since the last birth was associated with an increased risk (OR = 1.304; 95% CI: 1.111–1.530).…”

Eleven economically-significant tephritid pest species present in Australia. by Sabira Sultana (6666196)

The trend of risk scores. by Ayako Shoji (78037)

Flow Chart of Study Participant Selection. by Zhi Jin (3742471)

Subjects:

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Discovery of Novel Oxazepine Derivatives as Akt/ROCK Inhibitors for Growth Arrest and Differentiation Induction in Neuroblastoma Treatment by Jinxin Che (791250)

“…Treatment with <b>B12</b> results in the arrest of G0/G1 cell cycles, a significant decrease in N-myc protein level, and an increase in differentiation markers. …”